Pharma firms shares plunge after pausing marketing of Covid-19 test

A Covid-19 lateral flow test has been found to be less effective at detecting the Omicron variant, which has prompted companies to pause its marketing.    Rapid test developer Abingdon Health and biopharmaceutical firm Avacta announced this morning that their AffiDX lateral flow has “reduced sensitivity”, which prompted investors to duck out of the stock. [...]